The US Food and Drug Administration has granted Juul e-cigarettes authorisation for its devices and menthol and tobacco-flavoured cartridges, ending years of regulatory battles over the company’s role in creating a youth vaping epidemic.

The controversial decision comes despite fierce opposition from lawmakers and health advocates who maintain the company deliberately targeted teenagers. Senator Dick Durbin condemned the move, claiming the Trump administration “does not care about our kids.”

A Company Built on Youth Appeal

The Juul e-cigarettes authorisation follows extensive litigation and a $1.7 billion settlement over accusations that the company marketed highly addictive nicotine products to vulnerable young people. At the crisis peak in 2019, 27% of high school students reported vaping – a figure that alarmed parents, educators, and health professionals nationwide.

Juul’s original products featured flavours like mango and crème brûlée that critics argued were designed specifically for children and teenagers. The company only discontinued these flavours in mid-2019 under intense regulatory pressure and public outcry.

Chief Executive K.C. Crosthwaite claims underage use has dropped 98% since 2019 to just 0.5% of youth. This dramatic reduction occurred only after removing youth-appealing flavours and facing unprecedented regulatory oversight, highlighting how dangerous the original products were for young people.

Questionable Standards for Public Health

The Juul vaping device approval required demonstrating the products were “appropriate for the protection of public health.” Juul met this standard partly by showing approximately two million adults used their devices to quit smoking traditional cigarettes.

However, mounting evidence suggests e-cigarettes carry significant health risks of their own. The FDA emphasised that authorisation “does not mean these tobacco products are safe” and warned of strict monitoring for youth protection compliance.

Dr. Marty Makary, the FDA commissioner, has pledged aggressive enforcement against unauthorised Chinese e-cigarettes featuring appealing designs like tiny video game consoles and candy flavours. This suggests clear recognition that certain product features specifically target young users – the same concern that plagued Juul’s original offerings.

Market Changes Hide Ongoing Risks

Since Juul applied for authorisation in 2020, the e-cigarette market has transformed significantly. While major US manufacturers stopped selling flavoured products except menthol, Chinese imports flooded the market with fruit and candy flavours that remain popular among teenagers.

Teen vaping rates have declined from their 2019 peak to fewer than 8% of high school students in 2024. However, this improvement occurred primarily after removing the youth-appealing elements that made Juul’s original products so controversial.

Many schools continue reporting high vaping rates, with teachers and students expressing frustration about tobacco control funding cuts. The persistence of vaping in educational environments suggests the Juul e-cigarettes authorisation may legitimise and reignite concerns about normalising e-cigarette use among young people.

Corporate Profits Over Youth Protection

The timing of the Juul vaping device approval raises serious questions about prioritising economic interests over youth protection. The company faced thousands of lawsuits alleging it deliberately exploited nicotine’s addictive properties to create a new generation of dependent users.

Senator Durbin’s criticism that the decision represents “giving the green light to Big Tobacco to continue lining their pockets by peddling poison” reflects widespread concerns about industry influence on regulatory decisions.

The FDA has previously authorised e-cigarettes from major tobacco companies including Reynolds American and Altria, suggesting a concerning pattern of accommodating industry interests despite mounting youth protection concerns.

Inadequate Oversight Mechanisms

The Juul e-cigarettes authorisation includes requirements for ongoing monitoring and compliance with youth protection measures. However, the effectiveness of such oversight remains highly questionable given the company’s documented history of problematic marketing practices.

Crosthwaite now supports creating “an orderly, reliable market” with products manufactured in FDA-inspected facilities and marketed responsibly. This acknowledgment that previous practices were inadequate raises fundamental questions about why authorisation was granted to a company with such a troubled track record.

The FDA’s promise to monitor compliance closely and act against violations will be crucial for determining whether the Juul vaping device approval serves genuine public health interests or primarily benefits corporate profits.

Setting a Dangerous Precedent

The decision to grant Juul e-cigarettes authorisation establishes a troubling precedent for how regulatory agencies balance adult smoking cessation against youth protection. While helping adults quit smoking represents a legitimate public health goal, it shouldn’t occur at the expense of exposing young people to addictive products.

The company’s massive settlement suggests significant harm occurred to young people, yet the same products that caused that harm now receive official government authorisation. This raises fundamental questions about accountability and whether companies can effectively purchase their way out of regulatory consequences.

Concerns for the Future

The Juul vaping device approval will likely reignite intense debates about e-cigarette regulation and youth protection. With Chinese imports continuing to flood the market with youth-appealing products, the decision appears to legitimise a product category that has proven extremely difficult to keep away from young people.

Health advocates will monitor closely whether Juul’s authorised products remain genuinely focused on adult smoking cessation or begin drifting back toward marketing strategies that appeal to young users.

The ultimate test of this Juul e-cigarettes authorisation will be whether it genuinely serves public health by helping adults quit smoking without creating new generations of nicotine-dependent young people. Given the company’s documented history of targeting youth, scepticism about this outcome appears entirely justified.

The decision sends a concerning message that companies can engage in harmful practices, face massive settlements, and still receive regulatory approval for the same products that caused the original problems.

Source: The New York Times